Collaborative Working Agreement Summary

1. Project Name:	**Design of an ePROMs (electronic patient reported outcome measures) tool in breast care pathways with NHS Gloucestershire**
2. Organisations involved with this Collaborative Working Project are:	Eli Lilly & Company (Lilly UK) Gloucestershire Hospitals NHS Foundation Trust
3. The objectives for this project are:	The objective of this project is to design a bespoke patient facing web-based tool for patients with breast cancer. The tool will capture patient reported outcomes (PROMs) such as toxicities and quality of life scores which will be displayed electronically in a patient and clinical dashboard to support decision making of the clinical team. The project will explore all governance requirements at Gloucestershire Hospitals NHS Foundation Trust for adoption of digital tools of this kind and understand what is required within the tool design to meet these requirements. The project will also cover mapping the clinical pathway to understand how and where to best embed the tool for greatest patient and clinical benefit. The web-based tool will be designed with the aims of empowering patients with breast cancer to better self-manage their disease, aid timely clinical decision making with the potential to improve clinical outcomes and improve clinic efficiency through implementing remote management for clinically well patients. With support from Lilly UK under this agreement, Gloucestershire Hospitals NHS Foundation Trust plans to contract a 3rd party vendor to design a bespoke web-based tool for patients with breast cancer, with associated patient and clinician dashboards to display data. Secondary outcome aims include: • Understanding the wants and needs of breast cancer patients with regards to digital healthcare through conducting patient surveys. • Comprehensive mapping of the full breast cancer pathway to baseline the existing service. • Gaining knowledge of the governance requirements for adoption of digital tools by NHS trusts • Development of a considerations guide before implementing ePROMs within a service to support other departments and organisations. This project will serve as a proof of concept and provide a guide on what to consider before implementing an ePROMs web-based tool across other NHS organisations.

PP-ON-GB-0357
August 2023

Collaborative Working Agreement Summary

4. Roles and Responsibilities, including any funding	Lilly UK: ● Joint development of all documentation required for a Collaborative Working Agreement, under Clause 20 of the ABPI Code of Practice 2021 – Collaborative Working. ● Project Management following a Prince 2 approach, including Stakeholder engagement planning, managing timescales and costs, communication planning and maintaining project documents. ● Quality Improvement & process consultancy including baselining current service efficiency. ● Facilitation of design workshops. Lilly will have no input into the actual design of the platform. ● Joint dissemination and ownership of results ● Publication on Lilly UK corporate website and in the ABPI repository ● Joint commitment with Gloucestershire Hospitals NHS Foundation Trust to demonstrate any benefits realised during this project to the NHS on a wider scale. ● Any Adverse Events identified for Lilly products during this project will be reported using the usual local reporting process. ● Approval of any outputs related to this Collaborative Working Agreement ● Review and approval of content and method of dissemination of any outputs related to the Collaborative Working Agreement. At no point will Lilly have access to any patient identifiable data. Lilly will not receive any human data for analysis. All clinical decisions and data analysis will be the sole responsibility of the NHS. Gloucestershire Hospitals NHS Foundation Trust ● Joint development of project initiation documentation ● Understanding and navigation of Trust process for entering into a collaborative Agreement with Lilly UK ● Provision of suitably qualified project manager to oversee project delivery. ● Stakeholder engagement at a strategic NHS level ● Provision of relevant HCPs, management personnel and administration staff to participate in workshops ● Development of assessments and web-based tool for use in clinical practice. ● Any adverse events will be reported by the Trust in line with their existing standard reporting procedures ● Jointly (with Lilly UK) publish results of the project on Lilly UK corporate website and in the ABPI repository. My Clinical Outcomes will be contracted by NHS Gloucestershire Trust as the ePROMs supplier. To include: ● Technology development and quality testing specific to this project

Collaborative Working Agreement Summary

	• Completion of relevant data governance and security documentation required by The Trust **Financial Arrangements Lilly UK** • Digital funding – Implementation £25,100+VAT • Pharmacy support - £9,900+VAT • Additional staff costs for Lilly internal team £20,196 Total investment £55,196 Lilly cash funding = £35,000 to be paid at project start **Financial Arrangements Gloucestershire Hospitals NHS Foundation Trust** • Total investments are attributed to staff costs for Gloucestershire internal team £20,000
5. The expected benefits for patients on delivery of this project are:	Collaborative working. Direct patient benefits not measured.
6. The expected benefits for the partner organisation(s) on delivery of this project are:	This project will serve to design an ePROMs tool to The Trust specifications and needs as well as understand the governance requirement to enable the ePROMs tool to be approved for use locally. After adoption of ePROMS the following benefits can be expected (relevant to this project though out of scope) • Validated toxicity scoring, using standard toxicity reports from the CTCAE (Common Terminology Criteria for Adverse Events) • Better clinical decision-making • More efficient service delivery, including remote tracking and triage • Reduced burden on clinicians • Reduced overall healthcare utilisation.
7. The expected benefits for Lilly UK on delivery of this are:	• This project will provide the blueprint to develop an ePROMs tool for breast cancer which Lilly may wish to offer other NHS organisations as a donation in the future (with no expectation of any benefit in return). • An understanding of the NHS governance process with regards to ePROMs tools will support the provision of a Lilly donated ePROMs tool in other therapy areas. • This project will provide an understanding of the type of clinical pathway design an NHS Trust would require for an ePROMs tool to be successful. • Publication of this project on Lilly UK corporate website and in the ABPI repository would demonstrate Lilly to be a valued partner to the NHS in innovation and may strengthen the Lilly Oncology brand reputation.